awmsg logo



telotristat ethyl (Xermelo®)


Reference No. 2037

Publication date:
12/12/2017


Appraisal information

telotristat ethyl (Xermelo®) 250 mg film-coated tablet


Company: Ipsen Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/12/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, telotristat ethyl (Xermelo®) cannot be endorsed for use within NHS Wales for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Statement of Advice (SOA)
Download